

Figure S3




Figure S3. The combination of minocycline and nanoliposomal irinotecan (nal-IRI) is tolerable by mice bearing human OVCAR-4 cells. Changes in mouse body weight were monitored longitudinally before and after treatment. The following treatments were given to mice at 7 days after subcutaneous OVCAR-4 (3×10^6 cells in 50% culture medium and 50% Matrigel) tumor implantation: (i) No-treatment (NT); (ii) Minocycline (Mn) (50 mg/kg was administered on day 7, which is followed by eight more cycles of Mn at 25 mg/kg body weight on the following days post-implantation: 8, 9, 10, 11, 14, 15, 17, 18); (iii) nal-IRI (nal-IRI; three doses at 5 mg/kg each, on days 11, 15, and 18); and (iv) Combination of Mn and nal-IRI. Recorded mouse weights were normalized to day 7 mouse weight ($n = 3 - 13$ mice per group). All changes in mouse weight were within 10% compared to the start of experiment, suggesting all treatments were tolerable by mice.